Peptron, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1997-11-21
- Employees
- 99
- Market Cap
- -
- Website
- http://www.peptron.co.kr
To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04783636
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
Phase 2
- Conditions
- Early Parkinson's Disease
- Interventions
- Drug: PT320 2.0 mgDrug: PT320 2.0mg PlaceboDrug: PT320 2.5 mg
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT04269642
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT00964262
- Locations
- 🇰🇷
Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath